221 related articles for article (PubMed ID: 26728893)
1. A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression.
Richards EM; Mathews DC; Luckenbaugh DA; Ionescu DF; Machado-Vieira R; Niciu MJ; Duncan WC; Nolan NM; Franco-Chaves JA; Hudzik T; Maciag C; Li S; Cross A; Smith MA; Zarate CA
Psychopharmacology (Berl); 2016 Mar; 233(6):1119-30. PubMed ID: 26728893
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacology of AZD2327: a highly selective agonist of the δ-opioid receptor.
Hudzik TJ; Maciag C; Smith MA; Caccese R; Pietras MR; Bui KH; Coupal M; Adam L; Payza K; Griffin A; Smagin G; Song D; Swedberg MD; Brown W
J Pharmacol Exp Ther; 2011 Jul; 338(1):195-204. PubMed ID: 21444630
[TBL] [Abstract][Full Text] [Related]
3. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
Rickels K; Mathew S; Banov MD; Zimbroff DL; Oshana S; Parsons EC; Donahue SR; Kauffman M; Iyer GR; Reinhard JF
J Clin Psychopharmacol; 2008 Apr; 28(2):235-9. PubMed ID: 18344738
[TBL] [Abstract][Full Text] [Related]
4. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
Hirschfeld RM; Weisler RH; Raines SR; Macfadden W;
J Clin Psychiatry; 2006 Mar; 67(3):355-62. PubMed ID: 16649820
[TBL] [Abstract][Full Text] [Related]
5. The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.
Kornstein SG; Guico-Pabia CJ; Fayyad RS
Hum Psychopharmacol; 2014 Sep; 29(5):492-501. PubMed ID: 25196042
[TBL] [Abstract][Full Text] [Related]
6. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD).
Cutler NR; Sramek JJ; Macpherson AE; Doss MG; Benes CO; Howard SF
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):685-94. PubMed ID: 7938559
[TBL] [Abstract][Full Text] [Related]
8. Quetiapine Extended Release Open-Label Treatment Associated Changes in Amygdala Activation and Connectivity in Anxious Depression: An fMRI Study.
Altinay M; Karne H; Beall E; Anand A
J Clin Psychopharmacol; 2016 Dec; 36(6):562-571. PubMed ID: 27768670
[TBL] [Abstract][Full Text] [Related]
9. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
[TBL] [Abstract][Full Text] [Related]
10. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline.
Bandelow B; Bauer M; Vieta E; El-Khalili N; Gustafsson U; Earley WR; Eriksson H
World J Biol Psychiatry; 2014 Feb; 15(2):155-66. PubMed ID: 24506289
[TBL] [Abstract][Full Text] [Related]
11. Ziprasidone augmentation for anxious depression.
Ionescu DF; Shelton RC; Baer L; Meade KH; Swee MB; Fava M; Papakostas GI
Int Clin Psychopharmacol; 2016 Nov; 31(6):341-6. PubMed ID: 27306192
[TBL] [Abstract][Full Text] [Related]
12. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression.
Thase ME; Demyttenaere K; Earley WR; Gustafsson U; Udd M; Eriksson H
Depress Anxiety; 2012 Jul; 29(7):574-86. PubMed ID: 22753280
[TBL] [Abstract][Full Text] [Related]
13. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
14. Effects of the δ opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse.
Hudzik TJ; Pietras MR; Caccese R; Bui KH; Yocca F; Paronis CA; Swedberg MD
Pharmacol Biochem Behav; 2014 Sep; 124():48-57. PubMed ID: 24857840
[TBL] [Abstract][Full Text] [Related]
15. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
16. Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial.
Ghajar A; Neishabouri SM; Velayati N; Jahangard L; Matinnia N; Haghighi M; Ghaleiha A; Afarideh M; Salimi S; Meysamie A; Akhondzadeh S
Pharmacopsychiatry; 2017 Jul; 50(4):152-160. PubMed ID: 27701683
[No Abstract] [Full Text] [Related]
17. Chamomile (Matricaria recutita) may provide antidepressant activity in anxious, depressed humans: an exploratory study.
Amsterdam JD; Shults J; Soeller I; Mao JJ; Rockwell K; Newberg AB
Altern Ther Health Med; 2012; 18(5):44-9. PubMed ID: 22894890
[TBL] [Abstract][Full Text] [Related]
18. Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
Fava M; Memisoglu A; Thase ME; Bodkin JA; Trivedi MH; de Somer M; Du Y; Leigh-Pemberton R; DiPetrillo L; Silverman B; Ehrich E
Am J Psychiatry; 2016 May; 173(5):499-508. PubMed ID: 26869247
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.
Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y
Hum Psychopharmacol; 2014 Jan; 29(1):64-72. PubMed ID: 24424707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
